Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(18 sites)

United States

Moffitt Cancer Center, Tampa, Florida

Northwestern University, Chicago, Illinois

University of Kansas Clinical Research Center, Fairway, Kansas

University of Kansas Cancer Center, Kansas City, Kansas

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas